Jump Financial’s Traws Pharma TRAW Stock Holding History

Jump Financial’s Portfolio TRAW Stock Details TRAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-927	Closed	-$59K	–	1974
2021 Q4	$59K	Buy	+927	New	+$74.5K	﹤0.01%	1296
2021 Q3	–	Sell	-740	Closed	-$128K	–	1569
2021 Q2	$128K	Buy	+740	New	+$167K	0.01%	953

Other funds holding TRAW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BPA

Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jump Financial's TRAW Position: Q1 2022 in Review

Jump Financial sold out of Traws Pharma (TRAW) in Q1 2022, closing a stake of 927 shares — an estimated $59K sold.

Jump Financial first reported a position in TRAW in Q2 2021 and held it in 2 quarters. The position peaked at $128K in Q2 2021. 30 funds tracked by Wall St. Rank hold TRAW as of Q1 2022.

Jump Financial reported no remaining Traws Pharma position as of Q1 2022 after selling out during the quarter.
Jump Financial sold 927 Traws Pharma shares in Q1 2022, an estimated $59K.
Jump Financial first reported a position in Traws Pharma in Q2 2021 and held it in 2 quarters.
Jump Financial's Traws Pharma position peaked at $128K in Q2 2021.
30 funds tracked by Wall St. Rank held Traws Pharma as of Q1 2022.

Based on Jump Financial's 13F filing for Q1 2022, filed 12 May 2022.